



Verastem to Ring the NASDAQ Stock Market Closing Bell and Host Annual Research and Development Day on July 10, 2014

July 8, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 8, 2014-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that it will ring the Closing Bell at the NASDAQ MarketSite in Times Square, New York City, on Thursday, July 10, 2014, at 4:00 p.m. ET.

The Closing Bell ceremony will take place immediately following the conclusion of the Company's annual Research and Development Day. A live webcast of the NASDAQ Closing Bell will be available starting at 3:45 p.m. ET at <http://new.livestream.com/nasdaq/live>.

Verastem's annual **Research and Development Day** is being held at the Hudson Theatre at the Millennium Broadway Hotel beginning at **12:30 p.m. ET**. The Company will provide updates regarding the status of its research and development efforts, anticipated clinical milestones and upcoming plans for its programs targeting cancer stem cells. To attend, please RSVP to verastem@argotpartners.com.

Date: Thursday, July 10, 2014

Time: 12:30 p.m. – 4:00 p.m.

Location: The Hudson Theatre at the Millennium Broadway Hotel, 145 West 44th Street, New York, NY

RSVP: verastem@argotpartners.com

Webcast: <http://bit.ly/1IUF9cV>

A replay of the webcast will be archived for 90 days following the presentation date.

Conference Call Dial-in (U.S.): 866-906-7447

Conference Call Dial-in (International): 617-939-0999

Conference Call Passcode: 5946305

Replay Dial-in (U.S.): 888-799-6166

Replay Dial-in (International): 857-288-2550

Replay Passcode: 5946305

The invitation can be accessed here: [VSTM R&D Day Invitation](#)

****Lunch will be served****

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do

so.

Source: Verastem, Inc.

Verastem, Inc.

Brian Sullivan, 617-252-9314

bsullivan@verastem.com